Skip to main content

PEDS DIABETES

02963766

PEDS DIABETES

Associated Conditions

DiabetesType 2 Diabetes

Principal Investigator

Sponsor

Lilly USA, LLC

The purpose of this study is to determine how dulaglutide compares to placebo (a shot that does not contain any active medicine) in children and teens with type 2 diabetes who are treated with diet and exercise, and who may also be taking metformin and/or long-acting insulin. 'Investigational' means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). Dulaglutide is an investigational drug and this is the first time dulaglutide has been tested in children or teens.

This study is currently enrolling.


Interested in participating?

Fill out the information below and we will reach out to you within two business days with more information on qualifications for this trial and how to participate.